THE NUMBER NOBODY PUT ON THE COMPLIANCE CALENDAR
Twenty-six percent of physicians in the AMA's 2025 prior authorization survey report that prior authorization led to a serious adverse event for a patient in their care. Hospitalization. A life-threatening event. Permanent damage, or death. Twenty-four percent of those same physicians say their EHR offers electronic prior authorization for prescription medications at all. Put those two numbers side by side and you can see the next eight weeks coming. Jan. 1, 2027 arrives, federally regulated payers clear the bar, the press release writes itself, and the physician treating somebody's mother still works the phone tree at 7 p.m. because her EHR never shipped the feature.

WHAT THE SURVEY ACTUALLY SAYS
The AMA fielded this survey in December 2025 among 1,000 practicing physicians. Ninety-five percent say prior authorization delays access to necessary care. Inside that 26% reporting a serious adverse event, 20% name a hospitalization, 22% name a life-threatening event or an intervention to prevent permanent impairment, and 8% name disability, permanent bodily damage, a congenital anomaly or death. Physicians and their staff spend 13 hours a week on prior authorization. Thirteen hours. Somebody added a second job to a clinical practice and funded none of it.
Then comes the part that should end the debate about whether the process works as designed. Thirty-two percent of physicians say payers often or always deny their prior authorization requests. Fifty-nine percent skip the appeal entirely, because past experience taught them the appeal fails. Read that twice. Most of the doctors who believe a denial got the clinical question wrong let it stand, and the patient absorbs that decision as if a clinician made it.
The policy calendar sits on top of all of it. On Nov. 6, 2026, the AMA urged CMS to hold the Jan. 1, 2027 electronic prior authorization compliance date for federally regulated payers. CMS's own proposed rule, CMS-0062-P, which the agency described in its April 10, 2026 fact sheet, would require impacted payers, meaning Medicare Advantage organizations, Medicaid and CHIP fee-for-service, Medicaid managed care, CHIP managed care entities and FFE qualified health plan issuers, to support electronic prior authorization for drugs beginning October 1, 2027, with small health plans getting 36 months after the final rule effective date. Payer APIs get a deadline. The prescriber's desk gets nothing.
Yes, that Arnold Schwarzenegger.
He has a newsletter on beehiiv. So do Codie Sanchez, Jay Shetty, David Begnaud, Colin & Samir, and Joanna Stern.
They could publish just about anywhere. They chose beehiiv to build a direct connection with the people who want to hear from them most. And you can do the same, whether you’re world-famous or just at the start of your plan for world domination.
WHO BUILT IT THIS WAY
CMS wrote CMS-0062-P around payer APIs and attached no matching obligation to the prescriber side. So every impacted payer can satisfy the rule in full while 76% of physicians still have no electronic prior authorization path for drugs inside the software they open all day. The structure produces exactly what the structure rewards.
AHIP and its member plans signed a pledge on June 23, 2025 full of voluntary commitments, and published no denial rate, no turnaround time and no overturn rate alongside it. The AMA's survey concluded the impact of those commitments has not yet materialized. A promise with no metric amounts to a press release with a compliance calendar stapled to the back. EHR vendors own the other half of this. They shipped electronic prior authorization for prescription drugs to 24% of physicians, which reflects a product roadmap and a licensing line item, not a clinical limitation.
Now the part my own side has to own. Patient advocacy organizations and pharma advocacy budgets read the 2025 insurer pledge as a win. They funded awareness campaigns, webinars and toolkits against it, and staffed almost nothing against appeals capacity. I have sat through enough compliance countdowns to know which side of the desk gets ready, and it has never been the side with the patient sitting in front of it. Fifty-nine percent of physicians never file the appeal, and advocacy built no place for them to send the case. Nobody even collects the denials that go unchallenged, so the single strongest piece of evidence any of us could carry into a CMS comment period disappears every week.

WHAT THE GOOD ONES DO
The companies that treat access as an operating problem publish their own prior authorization numbers on a fixed calendar, by product and by payer type: request volume, denial rate, median turnaround, percentage overturned on appeal. They publish before a regulator asks and before a reporter calls. They also run an electronic prior authorization readiness check with their highest-volume prescriber sites, site by site, and they fix the EHR gap ahead of the compliance date instead of filing Jan. 1, 2027 under payer problems.
They staff the appeals desk with named people. They measure denials overturned per month, and they report that number internally next to sales figures. The median organization runs the same activity with none of the effect, counts materials distributed, and calls the quarter a success. Archō’s ELAVAY research has fielded annually since 2015 across more than 20 disease states, asking patient advocacy organizations, professional societies and community-based organizations how biopharmaceutical companies actually behave as partners. The 2025-2026 report puts a number on the distance. On payer engagement support, the help organizations need to fight coverage and reimbursement barriers, 141 respondents scored their interest at 4.75 on a seven-point scale. They scored what industry delivers at 3.30. Organizations asked for backup in the payer fight, and industry showed up 1.45 points short. That gap is the finding.

WHAT TO DO BEFORE JANUARY
Three moves, this quarter, each one assignable to a person by name. Assign somebody to audit your top 25 prescriber sites for electronic prior authorization capability for prescription drugs and report the raw count of sites that have it before Jan. 1, 2027, because the deliverable is the count and not a plan. Have your advocacy lead publish one page of your own prior authorization data for a single product this quarter: volume, denial rate, median turnaround, overturn rate. One product, one page, real numbers. Fund a one FTE appeals support pilot in a single therapeutic area and track denials overturned per month from day one, so the 59% of physicians who never appeal have somewhere to send the case.
If you want to know whether your advocacy function sits close enough to the decision to matter, take the Advocacy Influence Diagnostic. Free, anonymous, five minutes, and it returns an Advocacy Visibility Index and a Strategic Risk Score. The 2025/2026 ELAVAY Report is available now, and stay tuned for the opening of 2026/2027 fielding. Or email me directly: [email protected]



